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Background. The etiology of neurodegenerative disorders, such as the accelerated loss of dopaminergic neurons in
Parkinson’s disease, is unclear. Current hypotheses suggest an abnormal function of the neuronal sodium-dependent
dopamine transporter DAT to contribute to cell death in the dopaminergic system, but it has not been investigated whether
sodium-independent amine transporters are implicated in the pathogenesis of Parkinson’s disease. Methodology/Principal
Findings. By the use of a novel tandem-mass spectrometry-based substrate search technique, we have shown that the
dopaminergic neuromodulators histidyl-proline diketopiperazine (cyclo(his-pro)) and salsolinol were the endogenous key
substrates of the sodium-independent organic cation transporter OCT2. Quantitative real-time mRNA expression analysis
revealed that OCT2 in contrast to its related transporters was preferentially expressed in the dopaminergic regions of the
substantia nigra where it colocalized with DAT and tyrosine hydroxylase. By assessing cell viability with the MTT reduction
assay, we found that salsolinol exhibited a selective toxicity toward OCT2-expressing cells that was prevented by cyclo(his-
pro). A frequent genetic variant of OCT2 with the amino acid substitution R400C reduced the transport efficiency for the
cytoprotective cyclo(his-pro) and thereby increased the susceptibility to salsolinol-induced cell death. Conclusions/
Significance. Our findings indicate that the OCT2-regulated interplay between cyclo(his-pro) and salsolinol is crucial for nigral
cell integrity and that a shift in transport efficiency may impact the risk of Parkinson’s disease.
Citation: Taubert D, Grimberg G, Stenzel W, Scho ¨mig E (2007) Identification of the Endogenous Key Substrates of the Human Organic Cation
Transporter OCT2 and Their Implication in Function of Dopaminergic Neurons. PLoS ONE 2(4): e385. doi:10.1371/journal.pone.0000385
INTRODUCTION
Membrane transporters are essential for specificity and normal
function of a cell. Abnormalities in the function of neuronal
sodium-dependent monoamine transporters, such as the dopamine
transporter DAT, have long been implicated in the etiology of
a variety of neurodegenerative disorders including Parkinson’s
disease (PD).[1] However, the physiological and pathological roles
of other amine transporters in brain, such as the organic cation
transporter OCT2, are still unknown.
OCT2, which is encoded by the solute carrier (SLC) 22A2 gene,
is known to mediate sodium-independent electrogenic transport of
positively charged organic compounds of a wide range of different
molecular structures having sizes up to 350 Da.[2] It is therefore
classified as polyspecific transporter along with the organic cation
transporter OCT1 (SLC22A1) and the extraneuronal monoamine
transporter EMT (SLC22A3) that comprise a group of closely
related transporters with more than 50% amino acid sequence
identity localized to the chromosomal site 6q26. Also, OCT2 is
regarded to share extensively overlapping substrate specificities
with OCT1 and EMT.[2]
Based upon findings of high OCT2 expression in kidney and
OCT2-mediated translocation of cationic drugs and synthetic
model compounds like tetraethylammonium (TEA), current
hypotheses suggest that OCT2 is centrally involved in the renal
clearance of diverse cationic xenobiotics.[3] However, this
assumption about the functional role of OCT2 derives from
limited information. Expression of OCT2 has been assayed only in
a small number of tissues. In particular, functional implication of
the neuronal OCT2 localization reported[4,5] has not been
sufficiently explored. Moreover, to date, systematic investigations
to elucidate the endogenous substrates of OCT2 have not been
performed. In particular, low affinities and transport efficiencies
that have been observed for currently proposed biogenic OCT2
substrates – such as the catecholamines, serotonin, histamine or
tyramine[6] – suggest that the endogenous key substrates of OCT2
are still unidentified.
RESULTS AND DISCUSSION
A novel mass spectrometry based method for
systematic identification of substrates for cell
membrane transporters
The basic design to study the substrates of transporters is to
determine the uptake of a selected test substance into a cell line
that expresses the transporter of interest in comparison to the same
cell line lacking the transporter. The difference in intracellular
accumulation of the substance (which can be measured in the cell
lysates [7]) then reflects the specific transporter-mediated uptake.
To reliably identify the leading endogenous substrates of a trans-
porter this approach requires sequential testing of large numbers
of potential substrates in separate uptake experiments, which is at
best inefficient but often impracticable (e.g. due to limited
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developed a technique that allows the systematic identification of
the preferred endogenous substrates of a transporter in a single
uptake experiment by employing complex matrices derived from
blood or other organs containing the complete, but a priori
unknown spectrum of possible substrates. The compounds with
the highest cellular accumulation consequently represent the best
endogenous substrates. Analysis of these compounds is performed
in the cell lysates using liquid chromatography (LC) tandem mass
spectrometry (MS-MS) by repetition of a single ion monitoring
(SIM) algorithm for the mass range (m/z) in which the possible
substrates are expected to fall, as described in ‘Materials and
Methods’. Compared with full scan approaches that utilize only
the first MS dimension for detection, the use of the two-dimension
MS considerably raises sensitivity achieving detection limits in the
low nanomolar concentration range, and provides simultaneously
the unique fragment ion masses to a specific parent mass, which in
most cases allow the assignment of a structure to the substance.
Identification of a substrate with this method essentially depends
on the presence of the compound in the incubation matrix.
Therefore, we performed the uptake experiments by employing
fetal bovine serum as a concentrated mixture of a broad spectrum
of all endogenous compounds derived from the total organism. To
specifically address the role of OCT2 in the CNS an additional set
of uptake experiments was conducted with whole brain extract
from adult rats.
Identification and kinetic characterization of
histidyl-proline diketopiperazine and salsolinol as
endogenous key substrates of OCT2
Uptake experiments were conducted in OCT2-transfected human
embryonic kidney cells (HEK-293) by incubation with fetal bovine
serum. Specific OCT2-mediated uptake of a compound from serum
was assessed in comparison to HEK-293 cells without OCT2
expression by running positive electrospray ionization tandem mass
spectrometry analysis (ESI-LC-MS-MS). Significant specific uptake
(.2-fold above the control) was solely observed for the molecular
ions [M+H]
+ at mass-to-charge ratios m/z of 180 and 235, as
indicated by the difference chromatograms obtained from the SIM
experiments (Fig. 1A). The corresponding collision-induced disso-
ciation (CID) spectra could be assigned to salsolinol and histidyl-
proline diketopiperazine (cyclo(his-pro)), which was confirmed by
product ion spectra of the authentic standards (Fig. 1A). This result
was further confirmed by running the LC-MS-MS algorithm with
whole brain extract from adult rats as a source of potential
endogenous substrates (Fig. S1). Moreover, the presence of
significant concentrations of cyclo(his-pro) and salsolinol in fetal
bovine serum (FBS) and brain extractwas confirmed byLC-MS-MS
selected ion and selected reaction monitoring (FBS: 287 nmol/l
cyclo(his-pro) and 4.4 nmol/l salsolinol; brain extract: 132 nmol/l
cyclo(his-pro) and 3.8 nmol/l salsolinol).
Analysis of the transport kinetics of cyclo(his-pro) and salsolinol
uptake in OCT2-expressing HEK-293 cells revealed additional
evidence to suggest these compounds as specific endogenous key
substrates of OCT2:
1. The efficiency of transport (Vmax /Km) was higher than for
other endogenous compounds, including histamine and
tyramine, which were so far suggested to be the best
endogenous substrates of OCT2 (Fig. S2).[6] By compar-
ison, the catecholamine neurotransmitters (in particular the
salsolinol precursor dopamine) exhibited no significant
OCT2-mediated transport.[8]
2. The transport efficiency approximated the high level of the
unspecific OCT2 substrate TEA (Fig. 2A; Fig. S2).
3. HEK-293 cells expressing the isoform transporters OCT1
and EMT revealed considerably lower efficiency and
clearance for transport of cyclo(his-pro) and salsolinol
(Fig. 1, C and D).
4. Precursors, metabolites, and endogenous compounds struc-
turally related to cyclo(his-pro) and salsolinol failed to show
specific OCT2-mediated transport, except from N-methyl-
salsolinol that revealed about two-thirds of the salsolinol
uptake rate (Fig. 2, A and B).
5. Cyclo(his-pro) and salsolinol share common structural
features that appear to be essential for a specific OCT2
substrate (Fig. 2C). In agreement with the reported
characteristics of OCT2-mediated transport, uptake of
cyclo(his-pro) and salsolinol was found to be electrogenic in
translocating only the positively charged molecule (Fig. S3)
and independent of the transmembraneous sodium gradient
(Fig. S4).
Profiling of OCT2, cyclo(his-pro) and salsolinol in
dopaminergic brain areas
The specific biological roles of cyclo(his-pro) and salsolinol in
human physiology and pathophysiology are largely unknown. On
the basis of experimental and animal studies, it is hypothesized
that both compounds function as endogenous neuromodulators of
the central dopaminergic transmission.[9,10,11,12] Cyclo(his-pro)
is supposed to increase and salsolinol to decrease neuronal sensi-
tivity to dopamine. These effects were shown to take place without
direct interaction with dopamine receptors or changes in neuronal
excitability in the absence of dopamine.[9,10,11,13] In agreement
with the lacking affinity to catecholamine receptors, pharmaco-
logical characterization of transport into human dopaminergic
neuroblastoma (SH-SY5Y) and primary human glioblastoma
(HTZ-146) cells revealed that cyclo(his-pro) and salsolinol were
not translocated by the neuronal dopamine transporter (DAT) or
the neuronal norepinephrine transporter (NET); in addition, near
total abolishment of uptake in the presence of specific inhibitors of
the organic cation transporters indicated that no further trans-
porters were involved (Fig. 3, A and B). The failure of DAT to
translocate cyclo(his-pro) or salsolinol is also in keeping with
previous reports.[9,10,11,13] Further evidence for the failing
contribution of NET in cyclo(his-pro) or salsolinol transport was
obtained from uptake experiments in NET-transfected HEK-293
cells (Fig. S5).
Cyclo(his-pro) was initially discovered as a stable hypothalamic
metabolite of the thyrotropin-releasing hormone (TRH), but is also
synthesized de novo endogenously in the brain;[9] analysis of the
cyclo(his-pro) distribution in rat brain likewise indicates its
prevalence in dopaminergic areas (Fig. 3C). Salsolinol arises
from enzymatic condensation of dopamine with either acetalde-
hyde or pyruvic acid;[14] hence, highest concentrations were
detected in dopaminergic brain areas including substantia
nigra.[14] Intriguingly, OCT2 was found to be preferentially
expressed in the dopaminergic brain regions with the highest
central expression in substantia nigra pars compacta (SNc), the
area with the highest density of dopamine cell bodies in the CNS
(Fig. 3D). This finding agrees with a previous expression study of
our group in rat brain.[15] The demonstration of significant levels
of OCT2 in SH-SY5Y cells (Fig. 3D) and also in primary human
dopaminergic neuronal cells[5] further supports a prominent role
of OCT2 in the central dopaminergic system. In comparison with
OCT2 and Dopaminergic System
PLoS ONE | www.plosone.org 2 April 2007 | Issue 4 | e385Figure 1. Identification and transport kinetic characterization of cyclo(his-pro) and salsolinol as endogenous substrates of the organic cation
transporter OCT2. (A and B) Chromatograms and corresponding spectra of ESI-MS-MS fragmentation of the molecular ions [M+H]
+ at m/z 180 and
235 derived from lysates of OCT2-transfected HEK-293 cells versus empty vector transfected HEK-293 cells after 30 min of incubation with 100% fetal
bovine serum (pH 7.4, 37uC) following 60 min preincubation in buffer solution. Specific fragment masses are indicated in red and assigned to the
proposed fragment ion structures; the parent ions are shown in blue. (C and D) Concentration dependence, maximal transport rate Vmax (mean
(s.e.m.)) and Michaelis-Menten constant Km (mean (s.e.m.)) of specific uptake of cyclo(his-pro) or salsolinol into HEK-293 cells transfected with OCT2 or
the related cation transporters OCT1 and EMT after 1 min of loading (left panel); time dependence and influx clearance Clin (mean (s.e.m.)) of specific
uptake after incubation with 10 mmol/l of cyclo(his-pro) or salsolinol (right panel) (n=3 independent experiments each). N-methylation of
intracellular salsolinol was negligible (maximal 2.5% of salsolinol concentration after 60 min of incubation).
doi:10.1371/journal.pone.0000385.g001
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PLoS ONE | www.plosone.org 3 April 2007 | Issue 4 | e385Figure 2. Selectivity of cyclo(his-pro) and salsolinol as endogenous substrates of the organic cation transporter OCT2. (A and B) Accumulation of
selected compounds in HEK-293 cells expressing OCT2 (black bars) compared to cells expressing empty vector (open bars) after 5 min of incubation
with 10 mmol/l each (n=3, mean6s.e.m.; ***P,0.001). Substances showing significantly higher accumulation in OCT2 than in control cells (specific
OCT2-mediated transport) are depicted in blue; substances with equal accumulation in OCT2 and control cells (unspecific OCT2-independent
transport) are shown in red, and substances without detectable uptake in OCT2 or control cells are shown in black. (1: tertaethylammonium; 2:
cyclo(his-pro); 3: salsolinol; 4: N-methyl-salsolinol; 5: tyramine; 6: histamine; 7: 1,2,3,4-tetrahydroisoquinoline; 8: 1-methyl-3,4-dihydroisoquinoline; 9:
salsolidine; 10: tryptamine; 11: norharmane; 12: 6-methoxy-1,2,3,4-tetrahydro-b-carboline; 13: melatonin; 14: tetrahydropapaveroline; 15: carnosine;
16: thyrotropin-releasing hormone (TRH); 17: pyroglutamate; 18: 4-hydroxy-proline; 19: prolylalanine; 20: proline; 21: prolineamide; 22: glycylproline;
23: pyroglutamyl-histidine; 24: cyclo(tyr-pro)). (C) The overlay of energy minimized conformations (MM2 computation, Chem3D Pro software) of
native cylo(L-his-L-pro) (enol tautomer, endo-conformation)[24] and R-salsolinol uncovers close structural similarities, suggesting a planar ring system,
an electrophilic center, and a nucleophilic moiety with H-donor properties at a constant distance (of 6.560.3 A ˚) as key properties of a OCT2-specifc
substrate.
doi:10.1371/journal.pone.0000385.g002
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PLoS ONE | www.plosone.org 4 April 2007 | Issue 4 | e385Figure 3. OCT2, cyclo(his-pro), and salsolinol in brain. Uptake of cyclo(his-pro) and salsolinol (10 mmol/l, 5 min incubation) into human
neuroblastoma (SH-SY5Y) cells (A) and human glioblastoma cells (HTZ-146) (B) was not different from control conditions when coincubated with
selective inhibitors of dopamine (GBR12909, 10 mmol/l) or norepinephrine (desipramine, 10 mmol/l) transport, but was almost abolished after specific
inhibition of organic cation transport via OCT1, OCT2, and EMT with phenoxybenzamine (10 mmol/l) or decynium-22 (1 mmol/l)[25] (n=3,
mean6s.e.m.; ***P,0.001). OCT2 expression was similar in SH-SY5Y and HTZ-146 cells showing 35% and 32% of the level in substantia nigra
respectively. Levels of mRNA expression of DAT, NET, OCT1, and EMT in SH-SY5Y cells were 4.63%, 1.64%, 0.04%, and 0%, and in HTZ-146 cells 0%,
0.05%, 0.70%, and 0.37% of the respective OCT2 expression (=100%). Hence, neither the neuronal catecholamine transporters nor the isotypic cation
transporters OCT1 and EMT can account for a significant fraction of total uptake of cyclo(his-pro) and salsolinol in brain cells. (C) Concentration of
cyclo(his-pro) in rat brain divisions was highest in mesencephalon encompassing the dopaminergic region substantia nigra. In comparison, in rat
kidney (with the highest OCT2 expression)[15], cyclo(his-pro) concentration was lower, and in liver (lacking OCT2)[15], no cyclo(his-pro) was detected
(n=6, mean6s.e.m.; levels were not different between male (3) and female (3) rats; b.l.d.: below limit of detection). (D) Relative quantitative real-time
expression of OCT2 mRNA in distinct areas of normal human brain and neuroepithelial tumors (TaqMan Assay) normalized to GAPDH. Expression was
highest in substantia nigra pars compacta (SNc) and is given relative to an equally pooled sample derived from 30 normal donors aged 23–68 years
(relative expression=100%; black bar). Specimens of other normal brain areas were derived from a male donor aged 63 years; n.e. indicates no
expression of OCT2. The expression profile of the organic cation transporters and DAT in SNc with 0.048% (OCT1), 0.023% (EMT), and 3.66% (DAT)
respectively of the mRNA level of OCT2 (=100%) resembled that of SH-SY5Y cells which therefore represent an adequate model of OCT- and DAT-
mediated transport in SNc. (E) Correlation of OCT2, DAT, and tyrosine hydroxylase (TH) mRNA expression (relative to OCT2 in pooled SNc (=100%))
with intracellular concentrations of cyclo(his-pro), salsolinol and N-methylsalsolinol in microdissection preparations of total SNc, the SNc adjacent crus
cerebri (right section), and ventrolateral (VL), ventromedial (VM), and dorsolateral (DL) regions of SNc (left section) derived from a female donor aged
70 years. The neuron-specific expression profile of DAT and TH reflects the characteristic differences in the loss of dopaminergic neurons in SNc
regions with normal aging.[26]
doi:10.1371/journal.pone.0000385.g003
OCT2 and Dopaminergic System
PLoS ONE | www.plosone.org 5 April 2007 | Issue 4 | e385Figure 4. Selective cytotoxic effects of salsolinol and cytoprotective effects of cyclo(his-pro) toward OCT2-expressing cells. Cell viability was assessed
by MTT reduction assay; resulting formazane formation was determined by absorbance at 568 nm. (A) After 48 h exposure to different
concentrations of salsolinol, HEK-293 cells expressing OCT2 showed higher cell loss than HEK-293 cells expressing empty vector, OCT1 or EMT. The
respective EC50 values (95% confidence intervals) for salsolinol were 192 (174 to 212), 1112 (900 to 1375), 627 (525 to 748), and 998 (780 to
1277) mmol/l. 12 h of incubation with cyclo(his-pro) (10 mmol/l) prior to salsolinol treatment prevented degeneration of OCT2-transfected HEK-293
cells (EC50=763 (655 to 889) mmol/l), but had no effect on empty vector transfected HEK-293 cells (EC50=1073 (870 to 1324) mmol/l) (n=24–48;
mean6s.e.m.; *P,0.05, ***P,0.001). (B and C) Cytotoxicity of salsolinol and its protection by pretreatment with cyclo(his-pro) (10 and 100 mmol/l)
were confirmed in endogenously OCT2-expressing SH-SY5Y and HTZ-146 cells. The EC50 values in non-pretreated, and for 1 h with 10 mmol/l and
100 mmol/l cyclo(his-pro) pretreated SH-SY5Y cells were 49 (44 to 56), 1054 (888 to 1251), and 6568 (5313 to 8119) mmol/l of salsolinol, and the
respective values in HTZ-146 cells were 138 (120 to 160), 318 (268 to 377), and 2176 (1727 to 2741) mmol/l of salsolinol. (D and E) Cyclo(his-pro)
prevented SH-SY5Y and HTZ-146 cells from glutamate-induced cytotoxicity. EC50 values for glutamate were 389 (323 to 467) vs. 6461 (4132 to
10102) mmol/l in SH-SY5Y cells, and 585 (490 to 699) vs. 4768 (3660 to 6211) when comparing non-pretreated cells with cells pre-treated for 1 h with
10 mmol/l cyclo(his-pro). Cell death caused by glutamate (D and E) as well as salsolinol (B and C) was also attenuated in the presence of a specific
inhibitor of NMDA receptor-operated calcium channels ((+)-MK-801, 10 mmol/l), indicating that blockage of excitotoxic calcium entry may contribute
to the protective mechanism of cyclo(his-pro). The EC50 values for glutamate were 1986 (1744 to 2261) in SH-SY5Y and 2316 (1723 to 3112) mmol/l in
HTZ-146 cells, and the EC50 for salsolinol was 475 (430 to 524) in SH-SY5Y and 242 (202 to 291) mmol/l in HTZ-146 cells (n=16–32; mean6s.e.m.;
*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0000385.g004
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ble with only 0.048% and 0.023%, respectively in human SNc,
and 0.040% and 0%, respectively in SH-SY5Y cells. Analysis of
SNc subregions in human brain revealed a strong correlation of
OCT2 with the neuron-specific expression of DAT and tyrosine
hydroxylase (TH) along with the intracellular levels of the
endogenous OCT2 substrates. In contrast, the SNc adjacent area
of the crus cerebri lacked significant OCT2 expression; conse-
quently, intracellular concentrations of cyclo(his-pro), salsolinol
and N-methylsalsolinol were negligible (Fig. 3E). In comparison
to OCT2 expression in the brain, OCT2 levels in peripheral
tissues were all considerably lower than in SNc, apart from kidney
where OCT2 may be involved in the clearance of cyclo(his-pro)
(Fig. 3C; Fig. S6). These data *further support the notion of
a highly specific function for OCT2 in nigral dopaminergic
system.
Impact of OCT2 on neurodegeneration and
neuroprotection
Beyond its physiological neuromodulatory function, there is
considerable interest in the pathophysiologic role of salsolinol. In
patients with idiopathic Parkinson’s disease (PD) elevated brain
levels of salsolinol and its N-methylated derivatives were
observed.[14,16,17] It has been hypothesized that especially N-
methyl-salsolinol is etiologically involved in apoptotic nigral cell
death in PD by promoting calcium-triggered disruption of
mitochondrial permeability transition.[14] Here, we show that
Figure 5. Impact of the R400C polymorphism of OCT2 on transport kinetics. (A) Concentration dependence, maximal transport rate Vmax, and
Michaelis-Menten constant Km of specific uptake of cyclo(his-pro) or salsolinol into HEK-293 cells transfected with wild-type (wt) 400R or mutant (mt)
400C variant after 1 min of loading (n=3, mean6s.e.m). (B) Time dependence and influx clearance Clin of specific uptake after incubation with
10 mmol/l of cyclo(his-pro) or salsolinol (n=3, mean6s.e.m). For cyclo(his-pro), transport efficiency (Vmax/Km) and clearance of 400C were lower,
achieving 48% (P=0.0017) and 70% (P=0.002) of the 400R reference respectively. For salsolinol, transport efficiency and clearance showed no
significant differences between 400R and 400C (P=0.995 and 0.591 respectively). (C) Viability of HEK-293 cells expressing the OCT2 wild-type 400R or
mutant 400C variant was assessed by MTT reduction assay after 48 h exposure to different concentrations of salsolinol following 12 h of incubation
with cyclo(his-pro) (10 mmol/l). The 400C variant was less protected by cyclo(his-pro) against salsolinol-induced cell loss with an EC50 (95% confidence
interval) of 406 (321 to 513) mmol/l compared to 763 (655 to 889) mmol/l (P,0.001) for 400R (n=24–48; mean6s.e.m.; *P,0.05, ***P,0.001).
doi:10.1371/journal.pone.0000385.g005
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cells. Assessing cell viability by MTT reduction assay, we found
that salsolinol exposure (over 48 h) caused concentration-de-
pendent damage of OCT2-transfected HEK-293 cells as well as of
SH-SY5Y and HTZ-146 cells, which demonstrated a significant
endogenous OCT2 expression (Fig. 4, A to C). In contrast, HEK-
293 cells transfected with OCT1, EMT, or empty vector were
affected only at 3–5 fold higher salsolinol concentrations than the
OCT2-transfected HEK-293 cells (Fig. 4A). After 48 h incubation
of OCT2-transfected HEK-293 cells with 10 and 100 mmol/l
salsolinol, intracellular concentrations of the metabolite N-methyl-
salsolinol were 0.8960.06 and 7.5660.41 nmol/mg protein, with
SH-SY5Y cells 0.1860.01 and 1.2860.11 nmol/mg protein, and
HTZ-146 cells 0.1760.01 and 1.1660.06 nmol/mg protein
respectively (n=3; mean6s.e.m.). As no unchanged salsolinol
was detected, this suggests that the intracellular synthesized N-
methyl derivative represents the primary active cytotoxic agent.
Synthetic dipeptides that are structurally related to cyclo(his-
pro) have been reported to exert neuroprotective antiapoptotic
effects and to attenuate glutamate-induced elevations of in-
tracellular calcium.[18] Therefore, we asked whether cyclo(his-
pro) could prevent OCT2-expressing cells from salsolinol-induced
cell death and whether the protective effect also extends to
prevention of glutamate-induced excitotoxic cell injury. Pre-
treatment of OCT2-transfected HEK-293 cells for 12 h, or SH-
SY5Y and HTZ-146 cells for 1 h with cyclo(his-pro) prior to
incubation with salsolinol substantially diminished cell degenera-
tion (Fig 4, A to C). SH-SY5Y and HTZ-146 cells were also
shown to express subunits (NR1, 2a and 2b) of ionotropic NMDA
glutamate receptors, and consequently exhibited injury in response
to glutamate (Fig 4, D and E); the effect could be attributed to
NMDA receptor-activated Ca
2+ influx, since glutamate toxicity
was attenuated by coincubation with a selective antagonist of
NMDA receptor-gated calcium channels ((+)-MK-801, 10 mmol/
l). Similarly, pretreatment with cyclo(his-pro) (10 mmol/l) pre-
vented glutamate-induced damage of HTZ-146 cells (Fig 4, D
and E). In turn, the presence of (+)-MK-801 reduced salsolinol-
induced toxicity in HTZ-146 cells (Fig. 4, A to C). This suggests
that the protective mechanism of cyclo(his-pro) in neuronal cells
implies an inhibition of excitotoxic calcium influx, thereby
preventing mitochondrial impairment and subsequently apoptosis.
Impact of genetic variants of OCT2 on transport
kinetics of cyclo(his-pro) and salsolinol and cell
stress response
We further investigated whether the coding genetic variants of
OCT2 with allelic frequencies $1% in at least one ethnic
population (M165I, A270S, R400C and K432Q)[19] affect the
transport of the endogenous OCT2 brain substrates. For cyclo(his-
pro), the mutant 400C variant that occurs in African-Americans
with an ethnic-specific allelic frequency of 1.5%[19] exhibited
a significantly lower transport efficiency (Vmax/Km) and clearance
(Clin ) compared to the wild-type 400R variant; whereas for
salsolinol, transport kinetics were independent of the R400C
genotype (Fig. 5, A and B). In contrast, transport rates for
cyclo(his-pro) and salsolinol by the other OCT2 variants were not
different from the wild-type control (Tab. S1). Consequently,
HEK-293 cells transfected with the 400C genotype of OCT2 were
less protected against salsolinol-induced cytotoxicity by cyclo(his-
pro) pretreatment compared to the 400R genotype (Fig. 5C). This
indicates that the shift in transport efficiency between cytoprotec-
tive and cytotoxic OCT2 substrates caused by the R400C
substitution may increase susceptibility to cell death in the
dopaminergic neurons and impact risk for PD. However, whether
the R400C SNP is present to a greater degree in subjects with
idiopathic PD has to be addressed in subsequent trials.
Conclusion
We propose that the endogenous dopaminergic neuromodulators
cyclo(his-pro) and salsolinol are key substrates of OCT2. In-
terestingly, both substrates are abundant in the dopaminergic
brain region of the substantia nigra, where OCT2 shows its
highest expression in CNS. Intracellular OCT2-mediated balance
of salsolinol and cyclo(his-pro) appears to be crucial for
maintenance of dopaminergic cell integrity. A rise in potentially
cytotoxic salsolinol or a decline in protective cyclo(his-pro) may
cause calcium-triggered apoptotic cell death, possibly contributing
to the selective chronic nigral degeneration observed in PD.
In a broader perspective, our results provide the starting point
for more detailed investigations of the function of OCT2 in the
dopaminergic system and the potential association of genetically-
determined alterations in OCT2 function with PD. Furthermore,
the here presented technique provides principally new means to
identify the leading endogenous substrates of any cell membrane
transporter.
MATERIALS AND METHODS
Chemicals
Cyclo(tyr-pro), pyroglutamyl-histidine, prolyl-alanine, and glycyl-
proline were obtained from Bachem, salsolidine was from Carl
Roth, and 1-methyl-3,4-dihydroisoquinoline and tetrahydropapa-
veroline were from Arcos Organics. All other chemicals were
purchased from Sigma-Aldrich.
Cloning and cell culture
The cDNAs encoding the organic cation transporters OCT1
(GenBank accession no. NM_003057), OCT2 (NM_003058), and
EMT (NM_021977) were amplified by RT-PCR from human
liver, kidney, and placenta total RNA respectively, and subcloned
into the eukaryotic expression vector pcDNA3. The cDNA encod-
ing the norepinephrine transporter (SLC6A2) was kindly provided
by C. Pifl (University of Vienna). Genetic variants of OCT2
carrying a coding single nucleotide polymorphism (SNP) were
generated from wild-type, pcDNA3-inserted cDNA by mutant
oligonucleotide primers using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene). Human embryonic kidney cells
(HEK-293) were stably transfected with the respective vectors and
selected with geneticin as described.[8] Experiments were per-
formed on cell clones exhibiting an equal mRNA expression level
of the transporters, as determined by quantitative real-time PCR.
HEK-293 cells, the human neuroblastoma cell line SH-SY5Y and
the human glioblastoma cell line HTZ-146 (WHO grade IV) were
cultured in DMEM (Dulbecco’s Modified Eagle’s Medium, Gibco)
supplemented with 10% fetal bovine serum.
Transport experiments
For uptake experiments, cells were grown on polystyrene dishes of
60 mm diameter to at least 80% confluence. Prior to addition of
test compounds, culture medium was replaced by 3 ml HEPES-
modified Krebs buffer (140.0 mmol/l NaCl, 5.0 mmol/l KCl,
2.0 mmol/l CaCl2, 1.0 mmol/l MgCl2, 10.0 mmol/l HEPES, and
5.0 mmol/l D-glucose, adjusted to pH 7.40), and cells were left to
equilibrate for 60 min at 37uC. Uptake was terminated after
indicated times by washing cells with ice-cold buffer. Cells were
lysed with 1 ml of 4 mmol/l perchloric acid and lysates subjected
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determined after solubilization of perchloric acid precipitates with
1 ml of 0.1 mmol/l NaOH using the bicinchoninic assay (BCA
Protein Assay Kit, Pierce).
Substrate identification by ESI-LC-MS-MS
HEK-293 cells expressing OCT2 or empty vector were incubated
for 30 min with 100% fetal bovine serum (37uC, pH 7.4, Gibco) or
rat whole brain homogenates (37uC, pH 7.4) that were prepared as
described under ‘Determination of (cyclo)his-pro in rat brain’
below. After termination of uptake by washing with ice-cold
HEPES-Krebs buffer and protein precipitation with 4 mmol/l
perchloric acid or 100% acetonitrile in the case of brain
homogenates, lysates were analyzed by LC-MS-MS operating in
product scan positive electrospray ionisation mode (ESI) on a TSQ
Quantum triple-quadrupole tandem mass spectrometer equipped
withathermostated(5uC)Surveyorautosamplerandathermostated
(30uC) Surveyor HPLC system (Thermo Electron). Spray voltage
was set at 4500 V, and capillary temperature was kept at 350uC.
Nitrogen sheath gas and auxiliary gas pressure were 40 and 4 psi
respectively. The collision gas was argon and collision-induced
dissociation (CID) took place at 1.5 mTorr and 25 eV. 20 ml
aliquots of the samples were injected onto a 5 mm Hilic normal
phase column (10063.0 mm; Waters Atlantis), and eluted iso-
cratically at a flow rate of 0.25 ml/min (run time 8.0 min). The
mobile phase consisted of 70% (v/v) methanol/0.1% formic acid
and 30% (v/v) deionized water/0.1% formic acid. The resulting
CID chromatograms reflect the total ion currents caused by the
compound-specific ion transitions of the molecular ions [M+H]
+ of
a selected mass-to-charge ratio (m/z). 1-Methyl-4-phenyl-pyridi-
nium iodide (MPP
+, 500 ng/ml) was applied as internal standard
(IS) and the m/z 170R128 transition was simultaneously recorded
by single reaction monitoring (SRM) at 36 eV collision energy. The
respective CID chromatograms obtained in control and OCT2
uptake experiments were corrected for differences in retention time
of the IS (by shifting in x-direction) and for differences in peak area
of the IS and in protein content of the cells (by shifting in y-
direction). The difference chromatogram was generated from the
modified CID chromatograms by running the product scan filter
algorithm for the selected parent mass m/z. The ‘Background
subtraction’ command in Xcalibur software version 1.4 (Thermo
Electron) was applied to generate the difference chromatograms.
For each parent mass, the CID scan file obtained with control cells
was subtracted from the CID scan file obtained with OCT2 cells.
Offsets in retention time of IS were incorporated in the model by
specifying an alignment offset (in min), and offsets in IS area and
protein contentbyspecifyingaproportionalscaling factoraccording
to SF=(ISOCT26POCT2)/(IScontrol6Pcontrol), where ISOCT2,I S con-
trol: peak area of SRM chromatograms of IS in OCT2 and control
experiments, and POCT2,P control: protein concentrations of cell
lysates (in mg/ml) from OCT2 and control experiments. The
difference spectrum corresponding to a specific difference chro-
matogram represents the characteristic fragment ions of a com-
pound that is specifically transported by OCT2 and allows for most
species an unambiguous assignment of the empirical formula and
the chemical structure using mass spectral libraries (NIST MS
Search algorithm; MS-Manager, ACD-Labs). Product-ion scanning
analysis was repeated n-times for molecular ions of m/z=(100+n),
n=0,1,2…251 at a scan width of 0.5 each.
Quantification by LC-MS-MS
Chromatographic separations were performed on Hypercarb
(5 mm, 5062.1 mm; Thermo Electron), Aquasil C18 (3 mm,
10064.6 mm; Thermo Electron), or Hilic columns (5 mm,
10063.0 mm; Waters Atlantis) by isocratic or gradient elution
using 0.1% aqueous formic acid (A) and acetonitrile or methanol
(B) as solvent system. For quantification, SRM transitions of
a precursor ion [M+H]
+ into a specific fragment ion (peak area
ratios relative to IS) were recorded in positive ESI mode at 1.0–
1.5 mTorr collision pressure and 10–40 eV collision energy.
External calibration curves were obtained from serial dilutions of
the analyte in 4 mmol/l HClO4 by linear or logistic regression.
Detection limit was at least 0.001 nmol/mg protein. Compound-
specific SRM transitions analyzed were: cyclo(his-pro): m/z
235R110; cyclo(tyr-pro): 261R136; pyroglutamyl-histidine:
267R110; pyroglutamic acid: 130R86; salsolinol: 180R117; N-
methylsalsolinol: 194R151; salsolidine: 208R191; tetrahydropa-
paveroline: 289R123; proline: 116R70; prolineamide: 115R70;
hydroxyproline: 132R86; glycylproline: 173R116; (1,2,3,4-)-
tetrahydroisoquinoline: 134R115; tetraethylammonium:
130R86; 1-methyl-3,4-dihydroisoquinoline: 146R103; tyramine:
138R121; prolylalanine: 187R70; TRH: 363R249; histamine:
112R68; carnosine: 227R110; tryptamine: 161R144; melato-
nine: 233R174; norharmane: 169R89; 6-methoxy-1,2,3,4-tetra-
hydro-b-carboline: 203R174.
Extraction and quantification of mRNA
Multiple brain regions from a 63-year-old normal male were
resected at autopsy at the University Hospital of Cologne (16 h
postmortem), homogenized, and total RNA extracted by acid
guanidinium thiocyanate-phenol-chloroform extraction.[20] Hu-
man total RNA samples (BD Biosciences, Clontech) of kidney,
liver, pancreas, small intestine, colon, heart, skeletal muscle,
spleen, lung, mammary gland, ovary, prostate, testis, and sub-
stantia nigra pars compacta were pooled from normal tissues of
10–30 Caucasian individuals. Total RNA of peripheral blood
mononuclear cells (PBMCs, pooled from 5 healthy individuals)
and cell cultures were extracted by the Roche High Pure RNA
Isolation Kit. RNAs were reversed transcribed into cDNA by
using random hexamers and Superscript II Plus RNase H
2
Reverse Transcriptase (Invitrogen). Expression of SLC22A2
mRNA and in some experiments of SLC22A1, SLC22A3, NET
(SLC6A2), and DAT (SLC6A3), and tyrosine hydroxylase
(NM_199292.2) was determined from 10-ng samples of cDNA
(as estimated from ethidium bromide spot tests) by quantitative
real-time PCR (LightCycler, Roche Diagnostics) relative to the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) using TaqMan gene expression assays (Applied
Biosystems). Assay IDs were as follows: Hs00427550_m1
(OCT1), Hs00533907_m1 (OCT2), Hs00222691_m1 (EMT),
Hs01567436_m1 (NET), Hs00168988_m1 (DAT),
Hs00165941_m1 (TH), Hs99999905_m1 (GAPDH). Relative
quantifications were performed by pair-wise fixed reallocation
randomization test[21] and corrected for amplification efficiency
as evaluated from serial dilutions of cDNA. Repeated runs of the
same samples (standards or unknowns) gave a maximal variability
of 2–4% in CP values (interassay variation). Linearity of deter-
minations was confirmed over the entire working range of mRNA
expression (4–5 log values); failing expression was considered after
more than 45 cycles of amplification without increase in fluore-
scence intensity.
Determination of (cyclo)his-pro in rat brain
Complete brains were removed from heparinized and ether-
sacrified Sprague-Dawley rats of either sex, weighting 200–250 g,
dissected into its major anatomic divisions, washed in cold PBS,
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HCLO4 by sonication, and centrifugated at 3,000 g at 4uC for
10 min. Rat kidney and liver were prepared in the same way.
Concentrations of (cyclo)his-pro were measured in the super-
natants by ESI-LC-MS-MS. Limit of quantification was 20 pmol/
g of organ.
For uptake experiments (substrate search), homogenates of
whole brain in liquid nitrogen were extracted with HEPES-
modified Krebs buffer (pH 7.4, 10 ml per 3 g of homogenate) that
was pre-heated to 95uC to denature enzymes, then shock frozen,
and clarified by centrifugation at 20,000 g at 4uC for 30 min.
Microdissection of human substantia nigra
Left and right sections of the pars compacta of substantia nigra
(SNc) were separated at autopsy at the University Hospital of
Cologne from 3 mm cross sectional midbrain slices of the normal
brain of a 70-year-old woman (10 h postmortem) who died from
a duodenal ulcer and had no clinical or pathological history of
neuropsychiatric disease. The ventrolateral, ventromedial and
dorsolateral subdivisions of the ventral and dorsal tiers of the left
SNc were dissected out under microscopic control by use of
a microslicer. The SNc regions were washed with cold PBS and
homogenized in liquid nitrogen. One part was subjected to mRNA
extraction and quantitative PCR and the other to determination of
the intracellular concentrations of cyclo(his-pro), salsolinol and N-
methyl-salsolinol by means of LC-MS/MS as described above.
The lower limits of detection were 20 pmol/g tissue.
Toxicity assays
Cell viability was assessed in HEK-293 cells, human dopaminergic
neuroblastoma cells (SH-SY5Y) and human glioblastoma cells
(HTZ-146) by the MTT test as described.[22] Briefly, cells were
seeded onto 96-well plates (10,000 cells per well in 100 ml
medium), and after 48–72 h of culture (80–90% confluence)
incubated with salsolinol or glutamate for 48 h. In some cases,
cells were incubated for 12 h (HEK-293) or 1 h (SH-SY5Y and
HTZ-146) with 10 or 100 mmol/l (cyclo)his-pro prior to the
addition of salsolinol or glutamate. In other experiments, MK-801,
a selective antagonist of NMDA-receptor-gated calcium chan-
nels,[23] was concomitantly incubated with salsolinol or gluta-
mate. For indication of metabolic activity, cells were treated with
MTT reagent (15 ml of 1 mg/ml stock solution per well) for 1 h,
and after drying of culture plates for 1 h at 37uC, the resulting
formazan dye was extracted with isopropanol/HCl (100 ml
0.04 mol/l per well) and absorbance was determined spectropho-
tometrically at 568 nm. Results were in agreement with the data
obtained by the tryptan blue exclusion method (data not shown).
Kinetic and statistical analysis
Uptake velocity versus substrate concentration revealed saturation
kinetics and was fitted by the Michaelis-Menten equation: V0=
Vmax?[S]/(Km+[S]), where V0 and Vmax represent initial and
maximal transport velocity respectively (nmol/mg protein/min),
[S] initial substrate concentration (mmol/l), Km substrate concen-
tration at half maximal transport velocity (mmol/l), and Vmax/Km
efficiency of transport. Uptake versus time data were fitted by
linear one-compartment kinetics: cin(t)=cin,‘?(12e
2kex?t), where
cin(t) represents intracellular free substrate concentration after time
t (pmol/mg protein), cin,‘ extrapolated maximal intracellular free
substrate concentration (pmol/mg protein), and kex efflux rate
constant (1/min). Influx clearance was calculated as CLin=c in,‘/
cex?kex (ml/mg protein/min), with cex extracellular free substrate
concentration (pmol/ml). Statistical significance of differences
between two treatments was evaluated by the unpaired two-tailed
t-test or Mann-Whitney U-test, differences between more than two
treatments by one-way ANOVA or Kruskal-Wallis test, as
applicable. P,0.05 was considered statistically significant.
SUPPORTING INFORMATION
Table S1 Impact of frequent OCT2 variants on transport
kinetics of its endogenous key substrates
Found at: doi:10.1371/journal.pone.0000385.s001 (0.04 MB
DOC)
Figure S1 Identification of cyclo(his-pro) and salsolinol as
selective endogenous substrates of the organic cation transporter
OCT2 in the brain. Depicted are difference chromatograms and
corresponding spectra of ESI-MS-MS fragmentation of the
molecular ions [M+H]
+ at m/z 180 (salsolinol) (A) and 235
(cyclo(his-pro)) (B) derived from acetonitrile lysates of OCT2
transfected HEK-293 cells versus empty vector transfected HEK-
293 cells after 30 min of incubation with heat-inactivated rat
whole brain homogenates, following 60 min preincubation in
buffer solution. Specific fragment masses of the parent ions are
indicated in red.
Found at: doi:10.1371/journal.pone.0000385.s002 (1.62 MB TIF)
Figure S2 Efficiency of specific OCT2-mediated transport in
stably transfected HEK-293 cells after 1 min of incubation (n=3,
mean6s.e.m.). Cyclo(his-pro) and salsolinol exhibited higher
transport efficiencies (Vmax/Km) than tyramine and histamine
(P,0.001): Vmax/Km(CHP)=41, Vmax/Km(Sal)=21, Vmax/
Km(Tyr)=9, and Vmax/Km(His)=3 ml/mg protein/min. The
transport efficiency for cyclo(his-pro) differed not significantly
from the value for the tetraethylammonium (Vmax/Km=45ml/
mg protein/min; P=0.863), which represents an effective, but
unspecific model substrate of multiple transporters.
Found at: doi:10.1371/journal.pone.0000385.s003 (0.03 MB TIF)
Figure S3 The pH influenced specific uptake of cyclo(his-pro)
and salsolinol (10 mmol/l, 3 min incubation) in OCT2-transfected
HEK-293 cells, indicating electrogenic transport that requires net
positive charge. Cyclo(his-pro) and salsolinol are weak bases
(pKS=6.5–7.5); thus acidic pH increases and alkaline pH decreases
the proportion of protonated species (n=3, mean6s.e.m.).
Found at: doi:10.1371/journal.pone.0000385.s004 (0.90 MB TIF)
Figure S4 Specific uptake of cyclo(his-pro) and salsolinol
(10 mmol/l, 3 min incubation) in OCT2-transfected HEK-293
cells was independent of extracellular sodium concentration.
Sodium chloride was isoosmotically replaced with lithium
chloride; 50 nmol/l NaCl abolished the transmembraneous
sodium gradient (n=3, mean6s.e.m.).
Found at: doi:10.1371/journal.pone.0000385.s005 (0.91 MB TIF)
Figure S5 Comparison of specific uptake of cyclo(his-pro),
salsolinol, and tyramine (10 mmol/l, 5 min incubation) between
OCT2 and norepinephrine transporter (NET) transfected HEK-
293 cells revealed that cyclo(his-pro) and salsolinol are no
substrates of NET, while tyramine (positive control), in agreement
with previous findings,[1] was an excellent NET substrate (n=3,
mean6s.e.m.). 1. Burnette WB, Bailey MD, Kukoyi S, Blakely
RD, Trowbridge CG, et al. (1996) Human norepinephrine
transporter kinetics using rotating disk electrode voltammetry.
Anal Chem 68: 2932–2938.
Found at: doi:10.1371/journal.pone.0000385.s006 (0.90 MB TIF)
Figure S6 Quantitative real-time expression of OCT2 mRNA in
peripheral tissues (TaqMan Assay) normalized to GAPDH.
Expression is given relative to pooled substantia nigra (=100%).
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n.e. indicates no expression of OCT2, PBMC: peripheral blood
mononuclear cells.
Found at: doi:10.1371/journal.pone.0000385.s007 (0.88 MB TIF)
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